Skip to main content

Study M247

Study name

Glodzik-Sobanska L 2006

Title

Single voxel proton magnetic resonance spectroscopy in post-stroke depression

Overall design

The aim of this study was to evaluate metabolite ratios in the prefrontal regions of patients in both an early and a chronic phase of stroke. In a group of first-ever stroke patients, the authers studied the association between post-stroke depression and single voxel proton magnetic resonance spectroscopy (1H-MRS) measurements in unaffected frontal lobes. Twenty-six patients with a first ischemic stroke located outside the frontal lobes were included in the study. 1H-MRS was performed to assess N-acetylaspartate/creatine (NAA)/Cr, glutamate + glutamine (Glx)/Cr, choline (Cho)/Cr and myo-inositol (mI)/Cr ratios. Patients were assessed within the first 10 days after stroke and again four months later. Following the initial clinical assessments, the patient group was divided into a "depressed" group (stroke with depression group) and a "non-depressed" group (stroke without depression group). The diagnosis of depression was made on the basis of clinical observation, interview and Hamilton Depression Rating Scale scores. In a group of 26 patients, eight (31%) met criteria for depression at the first assessment, and nine (35%) met criteria for depression at follow-up. Metabolite quantification was reported relative to total creatine as the reference peak.

Study Type

Type1;

Data available

Unavailable

Organism

Human;

Categories of depression

Depressive disorder; Post-stroke depression; Post-stroke depression;

Criteria for depression

DSM-IV diagnosed MDD, HAMD-17 >= 13

Sample size

46

Tissue

Central; Brain; Frontal lobe;

Platform

MRS; MRS: 1.5 T proton-MRS scanner;

PMID

17088051

DOI

10.1016/j.pscychresns.2006.08.004

Citation

Glodzik-Sobanska L, Slowik A, McHugh P, et al. Single voxel proton magnetic resonance spectroscopy in post-stroke depression. Psychiatry Res 2006;148(2-3):111-20.

Metabolite

(Glutamate and Glutamine)/(Creatine and Phosphocreatine) ratio;